Caredx reiterates position that it does not infringe the ‘544 patent, injunction motion is irrelevant

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to natera, inc.'s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent). the motion seeks to stop caredx from using a prior allosure® process that natera alleged infringed the ‘544 patent. that proces.
CDNA Ratings Summary
CDNA Quant Ranking